Aprea Therapeutics Insiders Lose Out As Stock Sinks To US$4.23

The recent 10% drop in Aprea Therapeutics, Inc.'s (NASDAQ:APRE) stock could come as a blow to insiders who purchased US$122.0k worth of stock at an average buy price of US$7.29 over the past 12 months. This is not good as insiders invest based on expectations that their money will appreciate over time. However, as a result of recent losses, their original investment is now worth only US$70.8k.

While insider transactions are not the most important thing when it comes to long-term investing, we do think it is perfectly logical to keep tabs on what insiders are doing.

View our latest analysis for Aprea Therapeutics

The Last 12 Months Of Insider Transactions At Aprea Therapeutics

Over the last year, we can see that the biggest insider purchase was by Independent Director John Henneman for US$50k worth of shares, at about US$7.29 per share. So it's clear an insider wanted to buy, even at a higher price than the current share price (being US$4.23). While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. In our view, the price an insider pays for shares is very important. Generally speaking, it catches our eye when insiders have purchased shares at above current prices, as it suggests they believed the shares were worth buying, even at a higher price.

In the last twelve months Aprea Therapeutics insiders were buying shares, but not selling. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction!

Aprea Therapeutics is not the only stock insiders are buying. So take a peek at this free list of under-the-radar companies with insider buying.

Insider Ownership

Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. We usually like to see fairly high levels of insider ownership. From our data, it seems that Aprea Therapeutics insiders own 11% of the company, worth about US$2.5m. Overall, this level of ownership isn't that impressive, but it's certainly better than nothing!

So What Does This Data Suggest About Aprea Therapeutics Insiders?

The fact that there have been no Aprea Therapeutics insider transactions recently certainly doesn't bother us. But insiders have shown more of an appetite for the stock, over the last year. We'd like to see bigger individual holdings. However, we don't see anything to make us think Aprea Therapeutics insiders are doubting the company. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Aprea Therapeutics. At Simply Wall St, we've found that Aprea Therapeutics has 4 warning signs (1 can't be ignored!) that deserve your attention before going any further with your analysis.

But note: Aprea Therapeutics may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com